F. Mihaltan (Bucharest, Romania), M. Roberts (Leytonstone, United Kingdom)
Smoking-related disease events avoided quitting smoking – a simulated country perspective
J. Dollerup, P. B. Poulsen, H. Keiding (Ballerup, Copenhagen, Denmark)
|    |
Smoking cessation compared to treatment of COPD and other smoking-related diseases using cost-effectiveness evidence
J. Dollerup, P. B. Poulsen, H. J. Randskov, K. Møller Pedersen (Ballerup, Odense, Denmark)
| |
Pharmacoeconomics of bronchial asthma in novouralsk of Sverdlovsk region
E. Beltyukov, V. Naumova, M. Arkhipov (Ekaterinburg, Russian Federation)
| |
Health promoting behaviors and health literacy in asthma
D. Inal-Ince, S. Savci, H. Arikan, N. Vardar-Yagli, M. Bosnak-Guclu, M. Ozturk, G. Karakaya (Ankara, Turkey)
| |
Efficacy of education programme in patients with chronic obstructive pulmonary disease assessed by the lung information needs questionnaire
R. Wakabayashi, T. Ishii, T. Motegi, H. Kurosaki, N. Motohashi, K. Yamada, A. Gemma, R. Jones, K. Kida (Tokyo, Japan; Plymouth, United Kingdom)
| |
QVAR pMDI is more cost-effective than fluticasone propionate (FP) or CFC-beclometasone dipropionate (BDP) PMDI in a real-life asthmatic population receiving an increase in ICS dose
E. Sims, L. Kemp, P. Dorinsky, D. Price (Norwich, United Kingdom; Horsham, United States Of America)
| |
QVAR pMDI is more cost effective than CFC-beclometasone dipropionate (BDP) pMDI in a real-life asthmatic population initiating ICS
D. Price, L. Kemp, P. Dorinsky, E. Sims (Norwich, London, United Kingdom)
| |
Pharmaceutical cost of treatment in Greek COPD outpatients
C. Dimitropoulos, T. Tsoutsouras, M. Ntaganou, I. Kostara, G. Alexias, I. Ntanos (Athens, Greece)
| |